Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Nozomi Niitsu; Masataka Okamoto; Hirokazu Nakamine; Masami Hirano

doi:10.1016/j.leukres.2008.04.005

Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Nozomi Niitsu
, Masataka Okamoto
, Hirokazu Nakamine
, Masami Hirano

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

24 被引用数 (Scopus)

抄録

We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

本文言語	英語
ページ（範囲）	1837-1841
ページ数	5
ジャーナル	Leukemia Research
巻	32
号	12
DOI	https://doi.org/10.1016/j.leukres.2008.04.005
出版ステータス	出版済み - 12-2008
外部発表	はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

血液学
腫瘍学
癌研究

文献へのアクセス

10.1016/j.leukres.2008.04.005

他のファイルとリンク

引用スタイル

@article{92d22cef1a954dcf9b52697fef5da411,

title = "Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma",

abstract = "We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77\% and the 5-year overall survival was 87\%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.",

author = "Nozomi Niitsu and Masataka Okamoto and Hirokazu Nakamine and Masami Hirano",

note = "Funding Information: The authors thank for having had Dr. S. Nakamura, Dr. Oshima, Dr. Tamaru, Dr. N. Nakamura and Dr. Yoshino performing pathological diagnosis. Supported in part by a grant from the Ministry of Health and Welfare, and Grants-in-Aid for Scientific Research (C) and Cancer Research, from The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Japan.",

year = "2008",

month = dec,

doi = "10.1016/j.leukres.2008.04.005",

language = "English",

volume = "32",

pages = "1837--1841",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "12",

}

TY - JOUR

T1 - Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

AU - Niitsu, Nozomi

AU - Okamoto, Masataka

AU - Nakamine, Hirokazu

AU - Hirano, Masami

N1 - Funding Information: The authors thank for having had Dr. S. Nakamura, Dr. Oshima, Dr. Tamaru, Dr. N. Nakamura and Dr. Yoshino performing pathological diagnosis. Supported in part by a grant from the Ministry of Health and Welfare, and Grants-in-Aid for Scientific Research (C) and Cancer Research, from The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Japan.

PY - 2008/12

Y1 - 2008/12

N2 - We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

AB - We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

UR - https://www.scopus.com/pages/publications/51649089821

UR - https://www.scopus.com/pages/publications/51649089821#tab=citedBy

U2 - 10.1016/j.leukres.2008.04.005

DO - 10.1016/j.leukres.2008.04.005

M3 - Article

C2 - 18490056

AN - SCOPUS:51649089821

SN - 0145-2126

VL - 32

SP - 1837

EP - 1841

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

抄録

UN SDG

All Science Journal Classification (ASJC) codes

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル